Bluebird secures up to $175M financing amid gene therapy launches [Seeking Alpha]
Hercules Capital, Inc. (HTGC)
Last hercules capital, inc. earnings: 2/20 04:10 pm
Check Earnings Report
US:NYSE Investor Relations:
investor.htgc.com
Company Research
Source: Seeking Alpha
The biotech company said the transaction will help strengthen its balance sheet as it commercializes its gene therapies Lyfgenia for sickle cell disease, Zynteglo for beta thalassemia and Skysona for cerebral adrenoleukodystrophy. Bluebird said the term loan facility will provide up to $175M through four tranches. The company has already drawn on the first tranche of $75M. Bluebird will be eligible for two more tranches of $25M apiece, subject to the achievement of certain commercial milestones. The fourth tranche of up to $50M would be available at the sole discretion of Hercules Capital. The FDA approved bluebird's Lyfgenia for sickle cell disease in December, along with a rival gene therapy for the disease developed by Vertex Pharmaceuticals ( VRTX ) and CRISPR Therapeutics ( CRSP Recommended For You More Trending News Recommended For You More Trending News About BLUE Stock Related Stocks Trending Analysis Trending News
Show less
Read more
Impact Snapshot
Event Time:
HTGC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HTGC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HTGC alerts
High impacting Hercules Capital, Inc. news events
Weekly update
A roundup of the hottest topics
HTGC
News
- Hercules Capital Declares a Total Cash Distribution of $0.48 per Share for the First Quarter 2024Business Wire
- SynOx Therapeutics secures up to $35m debt financing with Hercules Capital to progress development and commercialisation of emactuzumab [Yahoo! Finance]Yahoo! Finance
- SynOx Therapeutics secures up to $35m debt financing with Hercules Capital to progress development and commercialisation of emactuzumabPR Newswire
- SynOx Therapeutics secures up to $35m debt financing with Hercules Capital to progress development and commercialisation of emactuzumabPR Newswire
- Hercules Capital (HTGC) Q1 Earnings Preview: What You Should Know Beyond the Headline Estimates [Yahoo! Finance]Yahoo! Finance
HTGC
Earnings
- 2/15/24 - Beat
HTGC
Sec Filings
- 4/23/24 - Form DEF
- 4/15/24 - Form 4
- 4/15/24 - Form 4
- HTGC's page on the SEC website